Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: A pilot study

Retina

Volumn 33, Issue 10, 2013, Pages 2096-2102

  Bousquet, Elodie ^a   Beydoun, Talal ^b,c   Zhao, Min ^a   Hassan, Leila ^b,c   Offret, Olivier ^b,c   Behar Cohen, Francine ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; DRUG EFFECT; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERKALEMIA; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PILOT STUDY; SUBRETINAL FLUID; TREATMENT DURATION; VISUAL ACUITY;

ADMINISTRATION, ORAL; ADULT; AGED; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULA LUTEA; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PILOT PROJECTS; PROSPECTIVE STUDIES; SPIRONOLACTONE; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84887086979     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318297a07a     Document Type: Article

References (27)

1. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008;115:169-173.
2. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-145.
3. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol 2013;41:201-214.
4. Gupta P, Gupta V, Dogra MR, et al. Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy. Int Ophthalmol 2010;30:175-181.
5. Quin G, Liew G, Ho I-V, et al. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Experiment Ophthalmol 2013;41:187-200.
6. Imamura Y, Fujiwara T,Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;29:1469-1473.
7. Jirarattanasopa P, Ooto S, Tsujikawa A, et al. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012;119:1666-1678.
8. Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011;31:1603-1608.
9. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-213.
10. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 1999;19:508-512.
11. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47:431-448.
12. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999;128:63-68.
13. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244-249.
14. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 2001;280:F181-F192.
15. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 2010;24:3405-3415.
16. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012;122:2672-2679.
17. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
18. Muldowney JA 3rd, Schoenhard JA, Benge CD. The clinical pharmacology of eplerenone. Expert Opin Drug Metab Toxicol 2009;5:425-432.
19. Steinle NC, Gupta N, Yuan A, Singh RP. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol 2012;96:10-13.
20. Meyerle CB, Freund KB, Bhatnagar P, et al. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 2007;27:943-946.
21. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011;31:1928-1936.
22. Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina 2011;31:766-771.
23. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983;95:457-466.
24. Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010;117:1792-1799.
25. Schaal KB, Hoeh AE, Scheuerle A, et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009;19:613-617.
26. Chan W-M, Lai TYY, Lai RYK, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008;115:1756-1765.
27. Delyani JA.Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-1411.